Lifestyle
- Manage stress through mindfulness or relaxation techniques
- Ensure adequate sleep
- Regular moderate exercise
Immunoglobulin A · IgA · Salivary IgA
IgA measures the concentration of immunoglobulin A antibodies in the blood or other body fluids.
Reference ranges may vary by laboratory and population. Age and sex-specific differences exist.
Immunoglobulin A (IgA) is a critical component of the immune system, primarily found in mucosal areas such as the gut, respiratory tract, and urogenital tract, as well as in saliva, tears, and breast milk. It plays a significant role in mucosal immunity by preventing the colonization of pathogens and neutralizing toxins. Clinically, IgA is important for diagnosing and monitoring autoimmune conditions such as IgA nephropathy, a common form of glomerulonephritis characterized by IgA deposition in the kidneys. Elevated IgA levels can indicate chronic infections, liver disease, or autoimmune disorders, while low levels may suggest immunodeficiency. In the context of athletic performance and biohacking, IgA is considered a marker of immune function, with implications for recovery and susceptibility to infections. Athletes often monitor IgA to optimize training loads and recovery strategies. However, IgA levels can be influenced by factors such as stress, hydration status, and recent infections, which should be considered when interpreting results. Researchers found that IgA levels can vary with circadian rhythms and may be affected by acute stress, as observed with interventions like L-Theanine, which can reduce stress-induced IgA fluctuations.
Klinische Bedeutung
Elevated IgA levels may indicate chronic infections, liver disease, or autoimmune disorders such as IgA nephropathy. Reduced IgA levels can suggest immunodeficiency or increased susceptibility to infections.
Increasing IgA levels may suggest worsening of chronic infections or autoimmune activity. Re-test in 4-6 weeks if elevated.
Decreasing IgA levels could indicate improvement in underlying conditions or potential immunodeficiency.
Re-test Interval
4-6 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if you have underlying health conditions.
IgA levels can vary with circadian rhythms; consistent timing of tests is recommended.
Testing Frequency
Annually for general health monitoring, more frequently if monitoring specific conditions.
May affect
Current research suggests that reference ranges and optimal targets for immunoglobulin A (IgA) in various diseases, such as IgA nephropathy and SARS-CoV-2 infection, remain poorly defined. Researchers have not yet established the impact of confounding factors, such as ethnicity and comorbidities, on IgA levels. Additionally, clinical questions regarding the predictive value of IgA as a biomarker for treatment response and disease progression in IgAN and viral infections remain unanswered.
1,121
Total Citations
11
Human/RCT
8.7
Avg. Influence
2025
Latest
This study examined the effects of L-Theanine on stress responses, finding that it significantly reduced heart rate and salivary immunoglobulin A (s-IgA) during stress tasks. Researchers observed that these effects may be linked to reduced sympathetic nervous system activation.
This study examined Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis, which can lead to chronic kidney disease. Researchers found that there is currently no specific biomarker to replace kidney biopsy for diagnosis, and significant variability exists in disease progression among different populations.
Researchers identified that gut microbiota-specific IgA+ B cells can traffic to the central nervous system (CNS) in multiple sclerosis (MS). The study found a strong IgA enrichment in active MS, suggesting a role for IgA in neuroinflammation. This highlights the potential of IgA as a biomarker for MS.
This study reviewed the clinical significance of Immunoglobulin A (IgA) deficiency, which is the most common primary immunoglobulin deficiency. Researchers found that while many individuals are asymptomatic, those with symptoms often experience severe infections and have associations with autoimmune diseases.
Researchers investigated the effects of Telitacicept on biomarkers in patients with Immunoglobulin A nephropathy (IgAN). They found significant reductions in galactose-deficient IgA1 and IgA-containing immune complexes, which were associated with decreased proteinuria, indicating a potential biomarker for treatment response.
Researchers explored the presence of immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein (MOG) in patients with central nervous system demyelination. They found isolated MOG-IgA in a subgroup of patients, suggesting it may serve as a novel diagnostic biomarker. The study indicates that MOG-IgA could be relevant in understanding the pathogenesis of demyelinating diseases.
Researchers explored the role of microscopic hematuria as a potential risk factor for progression in immunoglobulin A nephropathy (IgAN). The study discussed the challenges in standardizing hematuria assessments and called for its inclusion in clinical decision-making to guide treatment strategies in IgAN.
Researchers reported two cases of Immunoglobulin A vasculitis following COVID-19 vaccination. They observed symptoms such as purpura and arthritis, and noted that both patients responded well to treatment with prednisolone.
This study reviewed the role of Immunoglobulin A (IgA) in response to SARS-CoV-2 infection. Researchers emphasized that IgA serves as a critical mucosal antibody and a promising biomarker for early detection and diagnosis of COVID-19.
Researchers synthesized advances in the molecular pathogenesis of Immunoglobulin A nephropathy (IgAN) and proposed a new model called the 'spiral hypothesis' to explain the disease's chronic nature. They highlighted the potential of emerging targeted therapies and the importance of biomarker-guided treatment strategies.
Research publications about Immunglobulin A over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer